May 23, 2006
EnVivo Expands Management Team as Company Prepares First Drugs for Clinical Trials

June 27, 2005
EnVivo Appoints Kees Been as Chief Executive Officer

February 01, 2005
Methylgene and EnVivo sign HDAC Collaboration Agreement

November 09, 2004
EnVivo Pharmaceuticals Secures $23 Million Series B Funding

August 17, 2004
EnVivo Announces Hiring of Vice President of Chemistry

July 19, 2004
MethylGene and EnVivo Pharmaceuticals to collaborate in Neurodegenerative Diseases

December 05, 2003
EnVivo Appoints Several Leaders to Its Scientific Advisory Board

November 17, 2003
EnVivo Announces Key Additions to Its Management Team

October 27, 2003
EnVivo Pharmaceuticals Has Moved to Watertown, Massachusetts

October 06, 2002
EnVivo Pharmaceuticals Closes $14.7M Series A Round Led by Fidelity BioSciences Group

October 01, 2002
EnVivo Pharmaceuticals Awarded NIH Grant to Develop Technology for CNS Drug Discovery


Huntington’s Disease Summit – July 29, 2005

  • EnVivo hosted a summit on development of therapies for Huntington’s Disease that was attended by leading researchers and clinicians for Huntington’s Disease.


Therapeutic Strategies against Neurodegenerative Conditions (TSANC) – October 10-11, 2005, Boston, MA

  • Dr. Gerhard Koenig, CSO will give a presentation titled “Building a Pipeline of Novel Therapeutics for Neurodegenerative Diseases Using Phenotypic Screening”.


Mass Opportunities: A Biotechnology Investment Conference – November 3, 2005, Boston, MA

  • Kees Been, CEO will present at the upcoming Mass Opportunities conference.


BIO-Europe 2005 – November 7-9, 2005, Dresden, Germany

  • Kees Been, CEO will present at the upcoming BIO-Europe conference.